• patients
• To understand the association between the metabolic and skeletal abnormalities in HIV-infected subjects
• and their relationship to inflammation
• To determine whether treatment with w-3 fatty acids will have hypotriglyceridemic, anti-inflammatory, and anti-bone resorptive effects in a randomized trial of HIV-infected
• To clarify the mechanisms of action of u>-3 fatty acids, namely the effect on lipolysis and
• bone turnover using stable isotope infusion techniques.

• Total cholesterol
• LDL cholesterol
• HDL-cholesterol
• Markers of systemic inflammation
• Markers of bone turnover
• Markers of insulin resistance
• HIV-disease control (CD4+ counts, HIV viral loads)
• Measures of hepatotoxicity (ALT)
• Platelet function

The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we, the researchers, will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation.

Hypertriglyceridemia is common among HIV-infected patients receiving Highly Active Antiretroviral Therapy (HAART). Although fibrates, statins, and niacin have all been used in the management of hypertriglyceridemia in HIV-infected patients, optimal control is difficult to achieve and other agents are needed. Omega-3 fatty acids are effective for lowering triglycerides in patients without HIV infection, but experience in HIV-infected patients is limited. In addition, omega-3 fatty acids may also have secondary benefits in decreasing bone resorption and decreasing markers of systemic inflammation. The purpose of this study is to evaluate the efficacy and safety of omega-3-fatty acids in HIV-infected patients with hypertriglyceridemia. In addition, we will evaluate the effect of omega-3 fatty acid administration of markers of bone turnover and inflammation. It is 8- week randomized, double-blind trial of omega-3 fatty acids (OMACOR, Reliant, Inc) compared to placebo in 48 HAART-treated HIV-infected patients with triglycerides between 250 and 1000 mg/dl receiving dietary counseling. Subjects will be recruited from two centers (Johns Hopkins and Los Angeles VAMC). The primary endpoint will be the change in triglyceride concentrations from baseline in the OMACOR group compared to the placebo group. Secondary endpoints include the effect of OMACOR on other lipid targets (total cholesterol, LDL cholesterol, HDL-cholesterol), markers of systemic inflammation, markers of bone turnover, markers of insulin resistance, HIV-disease control (CD4+ counts, HIV viral loads), measures of hepatotoxicity (ALT), platelet function, and patient reports of adverse events. Omega-3 fatty acids may be a useful adjunct in the treatment of hypertriglyceridemia in HIV-infected patients, but additional controlled studies are needed to assess its safety and efficacy using a purified, standardized preparation.

• HIV Infections
• AIDS
• Dyslipidemia
• Hypertriglyceridemia

Inclusion Criteria:

• Ability and willingness to give informed consent
• Age ≥ 18 years
• HIV-1 infection documented at any time prior to study entry
• Fasting plasma triglyceride value between 250 and 1000 mg/dL on two occasions within 4 weeks
• Subjects must be receiving a stable antiretroviral medication regimen for > 3 months without any anticipated changes during the study interval
• Females must not be pregnant or lactating. Females of childbearing potential and males must use a reliable means of contraception
• On stable lipid modification pharmacotherapy for at least 8 weeks prior to study entry

Exclusion Criteria

• Hemoglobin A1C > 8.5 %
• Uncontrolled hypothyroidism (TSH > 4)
• HIV viral load > 5,000 copies/ml (cpm),
• Active liver disease and/or liver transaminases greater than 2.0 X upper limit of normal
• Active kidney disease or serum creatinine > 2.5 mg/dL
• Myocardial infarction, unstable ischemic heart disease, stroke, or coronary revascularization procedure
• Uncontrolled hypertension within 4 weeks of study entry (SBP > 180 mmHg or DBP > 100 mmHg)
• Use of systemic cancer chemotherapy within 8 weeks of study entry
• Pregnancy or breastfeeding
• Drug or alcohol dependence, or other conditions which may affect study compliance
• History of coagulopathy or use of anticoagulants such as warfarin
• Use of omega-3 fatty acid preparation in the 12 weeks prior to randomization
• Significant changes in clinical status from the Screening Visit which would preclude the patient from being an appropriate candidate.
• Any of the following laboratory parameters: hematocrit < 25%, absolute neutrophil count < 1.5 x 10^9/L, platelets < 100 x 10^9/L or hemoglobin < 8.0 gm/dL

• Reliant Pharmaceuticals
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• National Institute of Allergy and Infectious Diseases (NIAID)